LUNG CANCER

NSCLC with Multiple Sites of Metastasis and No Driver Mutation

Metastatic Lung Adenocarcinoma Without a Driver Mutation

Anna Farago, MD, PhD, assistant, medicine, Massachusetts General Hospital, discusses challenges in treating small cell lung cancer.

Durvalumab (Imfinzi) showed a modest but encouraging clinical benefit in patients with <em>EGFR</em>-mutant or <em>ALK</em>-positive non&ndash;small cell lung cancer with high tumor PD-L1 expression of &ge;25% in the third-line setting or beyond.

Jedd D. Wolchok, MD, PhD, chief, Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, discusses a phase 1/1b first in-human study of IPI-549, a PI3K gamma inhibitor as monotherapy and in combination with pembrolizumab (Keytruda) in patients with advanced solid tumors.

Julie R. Brahmer, MD, associate professor of Oncology, Bloomberg Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, discusses 5-year follow-up data from the CA209-003 study of nivolumab (Opdivo) in previously treated advanced non-small cell lung cancer (NSCLC).

Jason Chesney, MD, PhD, has been appointed director of the University of Louisville&rsquo;s James Graham Brown Cancer Center.

Ceritinib (Zykadia) has been recommended for approval by the EMA&rsquo;s Committee for Medicinal Products for Human Use for the treatment of patients with ALK-positive, metastatic non&ndash;small cell lung cancer.

The genetic profile of treatment-resistant non-small cell lung cancer may be more complex than initially thought, according to a presentation by Zofia Piotrowska, MD.

Rafal Dziadziuszko, MD, PhD, a global leader in clinical thoracic oncology, was recently honored with the 2017 Heine H. Hansen Award by ESMO and the IASLC.&nbsp;

More Stage I cancers were diagnosed after the passage of the Affordable Care Act within 5 screenable disease types (colorectal cancer, female breast cancer, cervical cancer, lung cancer, and prostate cancer) than were diagnosed before ACA implementation.

Julie R. Brahmer, MD, associate professor of Oncology, Bloomberg Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, discusses why CheckMate-026 was not successful in showing an improvement in progression-free survival (PFS) for patients with advanced non-small cell lung cancer.

Sarah B. Goldberg, MD, MPH, assistant professor of Medicine, Yale Cancer Center, discusses treating patients with non-small cell lung cancer (NSCLC) who do not have an actionable oncogenic driver.

Ramaswamy&nbsp;Govindan,&nbsp;MD, speaks to the rapid therapeutic changes and sequencing questions physicians are currently asking.

Pembrolizumab (Keytruda) has been granted an accelerated approval&nbsp;by the FDA for use in combination with pemetrexed plus carboplatin as a frontline treatment for patients with metastatic or advanced nonsquamous non&ndash;small cell lung cancer, regardless of PD-L1 expression.

Anna Farago, MD, PhD, discusses a phase I study of olaparib (Lynparza) and temozolomide (Temodar) in patients with small cell lung cancer who had progression after 1 prior line of platinum-based chemotherapy.